Abstract
To determine the causes of treatment failure and to evaluate the prognostic factors in patients hospitalized for community-acquired pneumonia, a prospective, observational study of 228 adult patients hospitalized for a community-acquired pneumonia in the University Hospital of Geneva and the La Chaux-de-Fonds Community Hospital, Switzerland, was conducted. The percentage of patients who failed to improve (as defined by guidelines of the Infectious Disease Society of America) and the causes of treatment failure were assessed, and patients who failed to improve under antimicrobial therapy were compared with those who did improve. In the 54 (24%) patients who failed to improve, a mean increase in length of hospitalization of 4 days was observed. Most causes of treatment failure could be attributed to host factors (61%) rather than to the pathogen (16%) or to an inappropriate antibiotic regimen (3%). After adjusting for potentially confounding variables, concomitant neoplasia (OR 3.25; 95%CI 1.11–9.56), neurological disease (OR 2.34; 95%CI 1.07–5.13), and aspiration pneumonia (OR 2.97; 95%CI 29–6.86]) were associated with failure to improve, whereas monocytosis improved prognosis (OR 0.40; 95%CI 0.20–0.80). Almost one out of four patients hospitalized for community-acquired pneumonia failed to respond to empirical antibiotic treatment. Aspiration pneumonia, concomitant neoplasia, and neurological disease were factors positively associated with failure to improve, whereas monocytosis was linked to a better prognosis.
Similar content being viewed by others
References
Niederman MS, McCombs JS, Unger AN et al (1998) The cost of treating community-acquired pneumonia. Clin Ther 20:820–837
British Thoracic Society Standards of Care Committee (2001) BTS guidelines for the management of community acquired pneumonia in adults. Thorax 56(Suppl 4):IV1–IV64
Marrie TJ (1998) Community-acquired pneumonia: epidemiology, etiology, treatment. Infect Dis Clin North Am 12:723–740
Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333:1618–1624
Mandell LA, Bartlett JG, Dowell SF et al (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433
Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754
Heffelfinger JD, Dowell SF, Jotgensen JH et al (2000) Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 160:1399–1408
Gleason PP, Kapoor WN, Stone RA et al (1997) Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 278:32–39
Dean NC, Silver MP, Bateman KA et al (2001) Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 110:451–457
Lim WS, Macfarlane JT, Boswell TCJ et al (2001) Study of community-acquired pneumonia aetiology in adults admitted to hospital: implications for management guidelines. Thorax 56:296–301
Metaly JP, Schultz R, Li Y-H et al (1997) Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157:1453–1459
Marrie TJ, Lau CY, Wheeler SL et al (2000) A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 283:749–755
Petitpretz P, Arvis P, Marcel M et al (2001) Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired pneumonia in adults. Chest 119:185–195
Fine MJ, Pratt HM, Obrosky DS et al (2000) Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 109:378–385
Genné D, Kaiser L, Kinge TN et al (2003) Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microb Infect Dis 9:1–6
Roson B, Carratalä J, Fernandez-Sabé N et al (2004) Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164:502–508
Arancibia F, Ewig S, Martinez JA et al (2000) Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 162:154–160
Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
Torres A, Sera-Battles J, Ferrer A et al (1991) Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 144:312–318
Bartlett JG, Dowell SF, Mandell LA et al (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 31:347–382
Fine MJ, Smith MA, Carson CA et al (1996) Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275:134–141
Cunha BA, Ortega AM (1995) Antibiotic failure. Med Clin North Am 79:663–672
Whitney CG, Farley MM, Halder J et al (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. Active Bacterial Core surveillance program of the Emerging Infections Program Network. N Engl J Med 343:1917–1924
El-Solh AA, Pietrantoni C, Bhat A et al (2003) Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 167:1650–1654
Van Eeden SF, Coetzee AR, Joubert JR (1988) Community-acquired pneumonia: factors influencing intensive care admission. S Afr Med J 73:77–81
Klemola E (1973) Cytomegalovirus infection in previously healthy adults. Ann Intern Med 79:267–268
Tsukahara T, Yaguchi A, Horiuchi Y (1992) Significance of monocytosis in varicella and herpes zoster. J Dermatol 19:94–98
Meuret G, Detel U, Kilz HP et al (1975) Human monocytopoiesis in acute and chronic inflammation. Acta Haematol 54:328–335
Turpin JA, Lopez-Berestein G (1993) Differentiation, maturation, and activation of monocytes and macrophages: functional activity is controlled by a continuum of activation. In: Lopez-Berestein G, Klostergaard J (eds) Mononuclear phagocytes in cell biology. CRC, Boca Raton, Florida, pp 71–76
Menedez R, Torrez A, Zalacain R et al (2004) Risk factors of treatment failure in community-acquired pneumonia: implications for disease outcome. Thorax 59:960–965
Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ (2001) Processes of care, illness severity, and outcome in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 161:2099–2104
Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE (1998) Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 279:1452–1457
Acknowledgements
The authors would particularly like to thank Dr. Carmen Pessoa Da Silva for her assistance in the statistical analysis in this study and Valentina Kostina for reviewing and helping with the preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
The results of this study were presented at the 11th International Congress on Infectious Diseases, March 2004, Cancun, Mexico.
Rights and permissions
About this article
Cite this article
Genné, D., Sommer, R., Kaiser, L. et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 25, 159–166 (2006). https://doi.org/10.1007/s10096-006-0113-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-006-0113-3